Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Navidea Biopharmaceuticals Inc NAVB

Healthcare Biotechnology
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on... see more

Recent & Breaking News (PINL:NAVB)

Navidea Achieves $1 Million in Lymphoseek® Commercial Milestones

Business Wire September 22, 2016

Navidea’s Lymphoseek® Receives Positive Opinion in Europe for a New Reduced Mass Vial

Business Wire September 16, 2016

Navidea to Present at Upcoming Investor Conferences

Business Wire September 14, 2016

Navidea Biopharmaceuticals to Hold Investor Update Call

Business Wire September 6, 2016

12 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  September 6, 2016

Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of Lymphoseek® in North America

Business Wire September 6, 2016

Navidea Biopharmaceuticals Announces 2016 Annual Meeting Results

Business Wire August 11, 2016

Navidea Executes a Term Sheet with Cerveau Technologies to Sublicense NAV4694

Business Wire August 8, 2016

Navidea Reports Second Quarter 2016 Financial Results

Business Wire August 4, 2016

Navidea Biopharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016

Business Wire July 28, 2016

Navidea Receives IRB Approval for its Lymphoseek® Rheumatoid Arthritis Clinical Trial Protocol

Business Wire July 19, 2016

Navidea Announces Presentation of Results Demonstrating Performance of Lymphoseek® in Breast Cancer at SNMMI

Business Wire June 16, 2016

Navidea to Provide Shareholder Update

Business Wire June 14, 2016

Navidea Announces Data Presentations at 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Business Wire June 2, 2016

$1.8 Million Fast-Track NIH SBIR Grant for Manocept™ Immunotherapeutics Evaluation in Kaposi’s Sarcoma Awarded to Navidea

Business Wire May 26, 2016

Navidea Provides Financing Update

Business Wire May 23, 2016

Navidea Reports First Quarter 2016 Financial Results

Business Wire May 17, 2016

Navidea Biopharmaceuticals to Announce First Quarter 2016 Financial Results on May 17, 2016

Business Wire May 10, 2016

Navidea and Macrophage Therapeutics to Provide Development Program Update

Business Wire May 3, 2016

Navidea Appoints Jed Latkin as Interim Chief Operating Officer

Business Wire April 26, 2016